Achilles Therapeutics plc (ACHL) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 London, 英国. 现任CEO为 Iraj Ali.
ACHL 拥有 IPO日期为 2021-03-31, 204 名全职员工, 在 NASDAQ Global Select, 市值为 $60.83M.
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
